Can the response to 23-valent pneumococcal vaccine in splenectomised patients be predicted?

被引：5
|
作者：
Llupia, Anna [1 ]
Vilella, Anna [1 ]
Costas, Laura [2 ]
Diez, Consolacion [1 ]
Torres, Ferran [3 ,4 ]
Yaguee, Jordi [5 ]
Masso, Montserrat [5 ]
Munoz, Ana [6 ]
Mensa, Josep [6 ]
机构：
[1] Hosp Clin Barcelona, Prevent Med & Epidemiol Dept, E-08036 Barcelona, Catalonia, Spain
[2] IDIBELL, Inst Catala Oncol, Canc Epidemiol Res Programme, Infect & Canc Unit UNIC, Lhospitalet De Llobregat 08908, Catalonia, Spain
[3] Hosp Clin Barcelona, IDIBAPS, Stat & Methodol Support Unit USEM, E-08036 Barcelona, Catalonia, Spain
[4] Univ Autonoma Barcelona, Sch Med, Biostat Unit, E-08193 Barcelona, Catalonia, Spain
[5] Hosp Clin Barcelona, Dept Immunol, E-08036 Barcelona, Catalonia, Spain
[6] Hosp Clin Barcelona, Dept Infect Dis, E-08036 Barcelona, Catalonia, Spain
来源：
VACCINE | 2012年 / 30卷 / 13期
关键词：
Splenectomy; Streptococcus pneumoniae; Response to vaccination; POLYSACCHARIDE VACCINE; ANTIBODY-RESPONSES; IMMUNOGLOBULIN-G; TRAUMA PATIENTS; INFECTION; ADULTS; IGG; VACCINATIONS; LYMPHOMA;
D O I：
10.1016/j.vaccine.2011.09.073
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The 23-valent pneumococcal vaccine has unequal effectiveness in splenectomised patients. We performed a longitudinal study (2005-2008) whose main objective was to characterize the profile of non-responders among splenectomised patients treated at our institution and identify potential predictive indicators of the response to the vaccine. The immune response was evaluated in 96 subjects. The proportion of responders was 70% (95% Cl: 60-78%). Immunosuppression (OR=3.19, 95% Cl 1.04-9.73) and the reason for splenectomy (hematologic neoplasia versus non-malignant hematologic diseases, OR=7.37, 95% CI 1.71-31.7) were independent predictors of non-response to vaccination. However, the positive predictive value of the model and the likelihood ratio for a positive result were low (PPV = 76.6%, 95% Cl 66.2-84.4%, LR(+)=1.41,95% Cl 1.08-1.86). We recommend determining the response to pneumococcal vaccine in these patients when possible. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2382 / 2386
页数：5
相关论文
共 50 条
  • [41] Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults
    Belmonti, Simone
    Rossetti, Barbara
    Modica, Sara
    Paglicci, Lorenzo
    Borghetti, Alberto
    Ciccullo, Arturo
    Picarelli, Chiara
    Cauda, Roberto
    De Luca, Andrea
    Montagnani, Francesca
    Lombardi, Francesca
    INFECTIOUS DISEASES AND THERAPY, 2019, 8 (03) : 453 - 462
  • [42] Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults
    Ahn, Jong Gyun
    Kim, Han Wool
    Choi, Hee Jung
    Lee, Jin Hwa
    Kim, Kyung-Hyo
    VACCINE, 2015, 33 (38) : 4770 - 4775
  • [43] Rethinking results from the Japanese 23-valent pneumococcal polysaccharide vaccine randomized clinical trial
    Gessner, Bradford D.
    Theilacker, Christian
    Jodar, Luis
    VACCINE, 2019, 37 (35) : 4853 - 4857
  • [44] The effect of 23-valent pneumococcal polysaccharide vaccine on immunological priming induced by 7-valent conjugate vaccine in asplenic subjects with β-thalassemia
    Orthopoulos, George V.
    Theodoridou, Maria C.
    Ladis, Vasilis A.
    Tsousis, Dimitris K.
    Spoulou, Vana I.
    VACCINE, 2009, 27 (03) : 350 - 354
  • [45] Dosing regimen of the 23-valent pneumococcal vaccination: A systematic review
    Caya, Chelsea A.
    Boikos, Constantina
    Desai, Shalini
    Quach, Caroline
    VACCINE, 2015, 33 (11) : 1302 - 1312
  • [46] Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease
    Ohshima, Nobuharu
    Akeda, Yukihiro
    Nagai, Hideaki
    Oishi, Kazunori
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (09) : 2285 - 2291
  • [47] The Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine versus 23-Valent Polysaccharide Vaccine in Adults Aged 50-80 Years
    Goldblatt, David
    Southern, Jo
    Andrews, Nick
    Ashton, Lindsey
    Burbidge, Polly
    Woodgate, Sarah
    Pebody, Richard
    Miller, Elizabeth
    CLINICAL INFECTIOUS DISEASES, 2009, 49 (09) : 1318 - 1325
  • [48] A possible relationship of natural killer T cells with humoral immune response to 23-valent pneumococcal polysaccharide vaccine in clinical settings
    Miyasaka, Tomomitsu
    Aoyagi, Tetsuji
    Uchiyama, Binei
    Oishi, Kazunori
    Nakayama, Toshinori
    Kinjo, Yuki
    Miyazaki, Yoshitsugu
    Kunishima, Hiroyuki
    Hirakata, Yoichi
    Kaku, Mitsuo
    Kawakami, Kazuyoshi
    VACCINE, 2012, 30 (22) : 3304 - 3310
  • [49] A Randomized Clinical Trial of the Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Compared to 23-Valent Polysaccharide Vaccine in Frail, Hospitalized Elderly
    MacIntyre, C. Raina
    Ridda, Iman
    Gao, Zhanhai
    Moa, Aye M.
    McIntyre, Peter B.
    Sullivan, John S.
    Jones, Thomas R.
    Hayen, Andrew
    Lindley, Richard I.
    PLOS ONE, 2014, 9 (04):
  • [50] Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months
    Russell, F. M.
    Balloch, A.
    Licciardi, P. V.
    Carapetis, J. R.
    Tikoduadua, L.
    Waqatakirewa, L.
    Cheung, Y. B.
    Mulholland, E. K.
    Tang, M. L. K.
    VACCINE, 2011, 29 (27) : 4499 - 4506
12345